The Relationship Between Serum Alkaline Phosphatase Levels and Survival Rate as a Prognostic Marker for Metastatic Spine Disease Patients

Oct 13, 2025 by magicalceylontours.com 39 views

The Relationship Between Serum Alkaline Phosphatase Levels and Survival Rate as a Prognostic Marker for Metastatic Spine Disease Patients

Introduction

Metastatic spine disease (MSD) is a serious condition with a poor prognosis and low life expectancy. Determining the life expectancy of MSD patients becomes crucial for appropriate treatment and support strategies. This study aims to examine the relationship between serum levels of alkaline phosphatase (ALP) as a prognostic marker for MSD patients.

Background

MSD is a condition where cancer cells spread to the spine, causing damage to the bone and surrounding tissues. The prognosis of MSD patients is often poor, with a low life expectancy. Determining the life expectancy of MSD patients is essential for developing effective treatment and support strategies. Alkaline phosphatase (ALP) is an enzyme that is often elevated in patients with bone metastases. Elevated ALP levels have been associated with a poor prognosis in various cancers.

Methodology

This study is a retrospective analytic descriptive study conducted at Adam Malik Haji Hospital Medan from September 2014 to December 2018. ALP level data from 28 MSD patients were analyzed to see their relationship with the patient's survival rate for 3-6 months, 6-12 months, and more than 12 months.

Results

The results showed that there was a significant difference in the survival rate of MSD patients based on ALP levels (p = 0.001). Patients with ALP levels of 20-140 IU/L have a life expectancy of more than 12 months, while patients with ALP levels 141-238 IU/L have a life expectancy of 6-12 months. Patients with ALP levels of more than 238 IU/L have a life expectancy of 3-6 months.

Further analysis shows that the average ALP levels are lower in groups of patients with a life expectancy of more than 12 months compared to groups of 6-12 months (78.77 (± 28.48) vs 182 (± 30.22)) IU /L. ALP content is also lower in groups of 6-12 months compared to groups 3-6 months (182.67 (± 30.22) vs 321.50 (± 32.92)) IU/L. This finding shows a statistically significant relationship (p = 0,000).

Discussion

The results of this study support the use of ALP serum levels as a prognostic marker in MSD patients. High ALP levels show poor prognosis and lower life expectancy. This finding can help doctors in determining the appropriate treatment and support strategies for MSD patients.

However, this research has several limitations, namely the number of limited samples and retrospective design. Further research with a larger number of samples and prospective design is needed to confirm this finding and determine the role of ALP in the management of MSD patients more comprehensively.

Conclusion

In conclusion, this study found a significant relationship between serum ALP levels and survival rate in MSD patients. High ALP levels are associated with a poor prognosis and lower life expectancy. This finding can help doctors in determining the appropriate treatment and support strategies for MSD patients. However, further research is needed to confirm this finding and determine the role of ALP in the management of MSD patients more comprehensively.

Limitations

This study has several limitations, namely the number of limited samples and retrospective design. Further research with a larger number of samples and prospective design is needed to confirm this finding and determine the role of ALP in the management of MSD patients more comprehensively.

Future Directions

Future research should focus on confirming the findings of this study and determining the role of ALP in the management of MSD patients. A larger sample size and prospective design are needed to confirm the relationship between ALP levels and survival rate in MSD patients.

Clinical Implications

The results of this study have clinical implications for the management of MSD patients. High ALP levels are associated with a poor prognosis and lower life expectancy. This finding can help doctors in determining the appropriate treatment and support strategies for MSD patients.

Recommendations

Based on the findings of this study, the following recommendations are made:

ALP serum levels should be used as a prognostic marker in MSD patients.
High ALP levels are associated with a poor prognosis and lower life expectancy.
Further research is needed to confirm the findings of this study and determine the role of ALP in the management of MSD patients.

Conclusion

Q: What is metastatic spine disease (MSD)?

A: Metastatic spine disease (MSD) is a condition where cancer cells spread to the spine, causing damage to the bone and surrounding tissues. MSD is a serious condition with a poor prognosis and low life expectancy.

Q: What is alkaline phosphatase (ALP)?

A: Alkaline phosphatase (ALP) is an enzyme that is often elevated in patients with bone metastases. Elevated ALP levels have been associated with a poor prognosis in various cancers.

Q: What is the relationship between serum ALP levels and survival rate in MSD patients?

A: The results of this study show that there is a significant relationship between serum ALP levels and survival rate in MSD patients. High ALP levels are associated with a poor prognosis and lower life expectancy.

Q: What are the implications of this study for the management of MSD patients?

A: The results of this study have clinical implications for the management of MSD patients. High ALP levels are associated with a poor prognosis and lower life expectancy. This finding can help doctors in determining the appropriate treatment and support strategies for MSD patients.

Q: What are the limitations of this study?

A: This study has several limitations, namely the number of limited samples and retrospective design. Further research with a larger number of samples and prospective design is needed to confirm this finding and determine the role of ALP in the management of MSD patients more comprehensively.

Q: What are the future directions for research on the relationship between serum ALP levels and survival rate in MSD patients?

A: Future research should focus on confirming the findings of this study and determining the role of ALP in the management of MSD patients. A larger sample size and prospective design are needed to confirm the relationship between ALP levels and survival rate in MSD patients.

Q: How can doctors use the results of this study to improve the management of MSD patients?

A: Doctors can use the results of this study to determine the appropriate treatment and support strategies for MSD patients. High ALP levels are associated with a poor prognosis and lower life expectancy, so doctors can use this information to develop more effective treatment plans.

Q: What are the potential benefits of using ALP serum levels as a prognostic marker in MSD patients?

A: The potential benefits of using ALP serum levels as a prognostic marker in MSD patients include improved treatment outcomes, better patient care, and more effective use of resources.

Q: What are the potential risks or limitations of using ALP serum levels as a prognostic marker in MSD patients?

A: The potential risks or limitations of using ALP serum levels as a prognostic marker in MSD patients include the potential for false positives or false negatives, the need for further research to confirm the findings of this study, and the potential for ALP levels to be influenced by other factors.

Q: How can patients and their families use the results of this study to improve their care and outcomes?

A: Patients and their families can use the results of this study to ask their doctors about the potential benefits and risks of using ALP serum levels as a prognostic marker in MSD patients. They can also use this information to advocate for more effective treatment and support strategies.

Q: What are the next steps for research on the relationship between serum ALP levels and survival rate in MSD patients?

A: The next steps for research on the relationship between serum ALP levels and survival rate in MSD patients include further studies to confirm the findings of this study and to determine the role of ALP in the management of MSD patients. A larger sample size and prospective design are needed to confirm the relationship between ALP levels and survival rate in MSD patients.